Clinical Trial News and Research

RSS

Cotinine can reduce plaques linked with dementia and prevent memory loss

Cotinine, a compound derived from tobacco, reduced plaques associated with dementia and prevented memory loss in a mouse model of Alzheimer's disease, a study led by researchers at Bay Pines VA Healthcare System and the University of South Florida found.

28 Apr 2011

The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of opioid dependence

Alkermes, Inc. today announced that results from the phase 3 clinical study of VIVITROL® (naltrexone for extended-release injectable suspension) in opioid dependence have been published by The Lancet. The six-month, phase 3 trial met its primary endpoint and showed significantly greater opioid-free weeks among patients treated with VIVITROL, compared to placebo.

28 Apr 2011

Enrollment complete in Unigene's oral PTH Phase 2 osteoporosis study in postmenopausal women

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company has completed patient enrollment of its Phase 2 study with an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women.

28 Apr 2011

Trig Medical to launch new standard for labor progression management at ACOG 2011

Trig Medical, Inc. announces the U.S. launch of LaborPro®, the new standard for labor progression management, at the American Congress of Obstetricians and Gynecologists (ACOG) 2011 Annual Clinical Meeting, taking place April 30 – May 4, 2011 in Washington, D.C. Trig Medical will be demonstrating the LaborPro system in Booth #824 during exhibition hours.

28 Apr 2011

Neovasc 2010 consolidated net loss decreases to $2,630,885

Neovasc Inc., today announced financial results for the year ended December 31, 2010.

27 Apr 2011

Spectranetics revenue increases 5% to $30.4 million for first quarter 2011

Spectranetics Corporation today reported financial results for the quarter ended March 31, 2011.

27 Apr 2011

Advanced Orthopaedics & Spine Medicine to participate in iUni G2 knee implant trial

Dr. David Mack of Advanced Orthopaedics & Spine Medicine and North Cypress Medical Center are participating in a ten year follow-up trial of the ConforMIS iUni® G2 knee resurfacing device, an FDA cleared implant for patients with osteoarthritic damage in a single compartment of the knee.

27 Apr 2011

Performance Orthopedics to participate in iUni G2 knee implant trial

Dr. Gregory Martin of Performance Orthopedics of the Palm Beaches is participating in a ten year follow-up trial of the ConforMIS iUni G2 knee resurfacing device, an FDA cleared implant for patients with osteoarthritic damage in a single compartment of the knee.

27 Apr 2011

CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC

In collaboration with Saladax Biomedical, Inc., the Central European Society for Anticancer Drug Research announced today that enrollment has begun in the CEPAC-TDM trial of paclitaxel therapeutic drug management with subsequent pharmacokinetic-guided dose adjustment in patients being treated for advanced non-small cell lung cancer.

27 Apr 2011

Nationwide researchers to launch Oncotype DX test phase III trial in breast cancer

Cancer researchers at hundreds of sites nationwide are about to launch a SWOG-led clinical trial that could keep thousands of breast cancer patients from getting chemotherapy that is unlikely to do them any good.

27 Apr 2011

Boehringer Ingelheim initiates enrollment in BI 201335 Phase 3 clinical trial for chronic HCV

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that enrollment has commenced at North American sites in its pivotal Phase 3 clinical trial program for BI 201335, the Company's investigational, oral protease inhibitor for the treatment of chronic hepatitis C virus (HCV).

27 Apr 2011

Brookside Surgery Center to participate in iUni G2 knee implant trial

Dr. Joseph Burkhardt of Brookside Surgery Center is participating in a ten year follow-up trial of the ConforMIS iUni G2 knee resurfacing device, an FDA cleared implant for patients with osteoarthritic damage in a single compartment of the knee.

27 Apr 2011

IQ Therapeutics completes dosing in IQNLF Phase I trial for anthrax

IQ Therapeutics has completed the dosing of antibody IQNLF in a Phase I clinical trial. A total of 36 healthy volunteers participated in the randomized, placebo controlled, double blind, single dose-escalating study, intended to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of IQNLF.

27 Apr 2011

FDA grants orphan drug status to Provectus' PV-10 for liver cancer treatment

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has received orphan drug designation by the U.S. Food and Drug Administration for Rose Bengal, the active ingredient in its novel oncology drug PV-10, for the treatment of hepatocellular carcinoma, the most common form of primary liver cancer.

27 Apr 2011

Diabetes and prediabetes are on the rise: New medication in research trials

As the newest statistics from the CDC show, diabetes is an ever increasing problem for Americans. Almost 26 million adults in this country now have diabetes, an increase of 9% since 2008. Ninety to 95% of cases are type 2 diabetes, marked by a gradual inability of the body’s cells to respond to insulin, and eventually an inability to produce enough insulin. In addition, almost 79 million people in this country have prediabetes. The CDC has warned that if diabetes continues on its current course, it could affect a third of all adult Americans by 2050.

26 Apr 2011

Common painkillers decrease effectiveness of antidepressants: Study

According to a latest study, antidepressants like Prozac and Aspirin do not mix. Researchers found that painkillers such as aspirin and ibuprofen appear to decrease the effectiveness of a popular class of antidepressants that includes Prozac, Paxil, Lexapro and Zoloft and Celexa.

26 Apr 2011

PolyMedix defensin-mimetic antibiotic compounds show antimicrobial efficacy against anthrax

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that several of its defensin-mimetic antibiotic compounds have shown antimicrobial efficacy in an animal model against the bacteria that causes anthrax.

26 Apr 2011

Colorectal cancer patients with genetic mutation can benefit from new class of drugs

A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.

26 Apr 2011

Men with high DHA levels may face risk of developing aggressive prostate cancer

The largest study ever to examine the association of dietary fats and prostate cancer risk has found what's good for the heart may not be good for the prostate.

26 Apr 2011

KemPharm to formulate and develop KP106 as oral film dosage for ADHD treatment

KemPharm, Inc. today announced that KP106, its clinical candidate for Attention Deficit/Hyperactivity Disorder, will be formulated and developed in an oral film dosage form pursuant to an exclusive collaboration agreement with MonoSol Rx relating to the development, commercialization and manufacture of KP106.

26 Apr 2011

Clinical Trial News and Research

Cotinine can reduce plaques linked with dementia and prevent memory loss

The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of opioid dependence

Enrollment complete in Unigene's oral PTH Phase 2 osteoporosis study in postmenopausal women

Trig Medical to launch new standard for labor progression management at ACOG 2011

Neovasc 2010 consolidated net loss decreases to $2,630,885

Spectranetics revenue increases 5% to $30.4 million for first quarter 2011

Advanced Orthopaedics & Spine Medicine to participate in iUni G2 knee implant trial

Performance Orthopedics to participate in iUni G2 knee implant trial

CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC

Nationwide researchers to launch Oncotype DX test phase III trial in breast cancer

Boehringer Ingelheim initiates enrollment in BI 201335 Phase 3 clinical trial for chronic HCV

Brookside Surgery Center to participate in iUni G2 knee implant trial

IQ Therapeutics completes dosing in IQNLF Phase I trial for anthrax

FDA grants orphan drug status to Provectus' PV-10 for liver cancer treatment

Diabetes and prediabetes are on the rise: New medication in research trials

Common painkillers decrease effectiveness of antidepressants: Study

PolyMedix defensin-mimetic antibiotic compounds show antimicrobial efficacy against anthrax

Colorectal cancer patients with genetic mutation can benefit from new class of drugs

Men with high DHA levels may face risk of developing aggressive prostate cancer

KemPharm to formulate and develop KP106 as oral film dosage for ADHD treatment

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer